Danaher Co. (NYSE:DHR) has been given a consensus rating of “Buy” by the eighteen brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $95.43.
DHR has been the topic of several recent analyst reports. Robert W. Baird reiterated a “buy” rating and set a $99.00 target price on shares of Danaher in a research report on Friday, December 15th. Citigroup increased their target price on Danaher to $107.00 and gave the stock a “buy” rating in a research report on Friday, December 15th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a research report on Thursday, October 5th. Cowen reiterated a “buy” rating and set a $90.00 target price on shares of Danaher in a research report on Wednesday, October 4th. Finally, Credit Suisse Group reiterated a “hold” rating and set a $99.00 target price on shares of Danaher in a research report on Tuesday, December 19th.
In other Danaher news, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total transaction of $11,671,620.96. Following the completion of the sale, the chief executive officer now owns 271,737 shares in the company, valued at approximately $25,173,715.68. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Daniel Raskas sold 37,870 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total value of $3,534,407.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 273,810 shares of company stock valued at $25,218,813. Insiders own 12.20% of the company’s stock.
Shares of Danaher (DHR) traded up $0.59 during trading hours on Friday, hitting $94.71. The stock had a trading volume of 1,841,590 shares, compared to its average volume of 2,741,167. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00. Danaher has a twelve month low of $78.97 and a twelve month high of $95.16. The stock has a market capitalization of $65,880.00, a P/E ratio of 28.19, a P/E/G ratio of 2.04 and a beta of 1.03.
Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The business had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same period in the prior year, the business earned $0.87 earnings per share. The business’s revenue was up 9.6% on a year-over-year basis. sell-side analysts forecast that Danaher will post 3.99 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be paid a $0.14 dividend. The ex-dividend date is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.59%. Danaher’s dividend payout ratio (DPR) is currently 16.67%.
TRADEMARK VIOLATION WARNING: “Danaher Co. (DHR) Receives Average Rating of “Buy” from Brokerages” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/05/danaher-co-dhr-receives-average-rating-of-buy-from-brokerages.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.